Abstract: Acute myocardial infarction with cardiac shock is a critical circulatory system disease that is difficult to cure. Despite the development and clinical application of mechanical circulation support and revascularization techniques, cardiogenic shock is still a high risk of death. As a new positive inotropic agent and calcium sensitizer, levosimendan has the dual effect of positive inotrophy and vasodilation. In recent years, related animal and clinical studies have confirmed that levosimentan is a more advantageous heart protective drug, as levosimentan has not only been used in the treatment of decompensated heart failure in cardiovascular system diseases, but also had certain protective effect on the lung, kidney and other organs of critically ill patients. Based on recent literature reports, this review summarized the mechanism of levosimendan and its research progresses in acute myocardial infarction complicated with cardiogenic shock to provide more diagnosis and treatment ideas for cardiogenic shock.